{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:37:46Z","timestamp":1773387466643,"version":"3.50.1"},"reference-count":26,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney Blood Press Res"],"published-print":{"date-parts":[[2005]]},"abstract":"<jats:p>&lt;i&gt;Aims:&lt;\/i&gt; To compare the efficacy, costs and safety of oral ganciclovir and valacyclovir in the prophylaxis of cytomegalovirus (CMV) disease in renal transplant (RTx) recipients at high risk of CMV disease. &lt;i&gt;Methods:&lt;\/i&gt; A total of 83 patients were prospectively randomized to 3-month treatment with either oral ganciclovir (3 g\/day) or oral valacyclovir (8 g\/day). A 3rd group received no prophylaxis. Forty-nine patients were considered to be at high risk of CMV disease due to D+R\u2013 serologic status, OKT3\/ATG treatment and\/or acute rejection within 12 months after RTx. Twenty-three high-risk patients were treated with ganciclovir (GAN group), 17 patients with valacyclovir (VAL group), and 9 patients received no prophylaxis (C group). &lt;i&gt;Results:&lt;\/i&gt; No significant differences were found among the groups in their demographic characteristics, immunosuppressive protocols, D\/R CMV serology, or CMV risk factors. The 12-month incidence of CMV disease was 89% in the C group compared with 9% in the GAN group and 6% in the VAL group (p &lt; 0.001, GAN or VAL vs. C; p = 0.713, GAN vs. VAL). Treatment failure (death, graft loss, CMV disease or withdrawal from study) occurred in 17, 6, and 89% in the GAN, VAL, and C groups, respectively (p &lt; 0.001, GAN or VAL vs. C; p = 0.285, GAN vs. VAL). The average CMV-associated costs per patient were EUR 3,161, 3,757, and 7,247 in the GAN, VAL, and C groups, respectively (p = 0.027). &lt;i&gt;Conclusion:&lt;\/i&gt; Valacyclovir and oral ganciclovir are equally effective in the prophylaxis of CMV disease in high-risk RTx patients. Both regimens are cost-effective and help reduce CMV-associated costs by nearly 50% compared with patients without prophylaxis.<\/jats:p>","DOI":"10.1159\/000087129","type":"journal-article","created":{"date-parts":[[2005,7,26]],"date-time":"2005-07-26T10:27:42Z","timestamp":1122373662000},"page":"218-225","source":"Crossref","is-referenced-by-count":18,"title":["Prospective Comparison of Valacyclovir and Oral Ganciclovir for Prevention of Cytomegalovirus Disease in High-Risk Renal Transplant Recipients"],"prefix":"10.1159","volume":"28","author":[{"given":"Tom\u00e1\u0161","family":"Reischig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Opatrn\u00fd Jr.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladislav","family":"T\u0159e\u0161ka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Mare\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Jindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslava","family":"\u0160vecov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2005,12,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2FS0002-9343%2897%2980021-6"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1600-6143.2002.20907.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097%2F00007890-199912270-00011"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097%2F00007890-200007270-00013"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1600-6143.2003.30114.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097%2F00007890-200011270-00012"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097%2F01.ASN.0000051599.09435.1E"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199806113382407"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097%2F00007890-199201000-00013"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1399-3062.1999.010304.x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1086%2F324516"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1399-0012.2000.140303.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2800%2902607-6"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097%2F00007890-199712270-00036"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199905133401903"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2F0732-8893%2887%2990020-4"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097%2F00007890-199812270-00019"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097%2F01.TP.0000150024.01672.CA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038%2Fclpt.1993.196"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.1999.00299.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1086%2F319225"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM198905253202105"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfg039"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1086%2F367836"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1600-6143.2004.00382.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001%2Farchinte.149.12.2733"}],"container-title":["Kidney and Blood Pressure Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/87129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/87129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:19:24Z","timestamp":1745464764000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000087129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000087129","archive":["Portico"],"relation":{},"ISSN":["1420-4096","1423-0143"],"issn-type":[{"value":"1420-4096","type":"print"},{"value":"1423-0143","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}